P1.193. Neoadjuvant Therapies vs Upfront Surgery for cT2N0 Oesophageal Cancer – a Systematic Review and Meta-Analysis

Clicks: 29
ID: 326137
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #5 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer Background In March 2026, the International Society for Diseases of the Esophagus (ISDE) made ‘conditional’ recommendations in support of neoadjuvant therapy (NAT) over primary surgical resection (PSR) for patients diagnosed with cT2N0 oesophageal cancer. Notwithstanding this, controversial exists due to potential overtreatment. Our aim was to perform a systematic review and meta-analysis to evaluate oncological and survival outcomes in patients with cT2N0 oesophageal cancer who have undergone NAT and PSR. Methods A systematic review was performed as per PRISMA guidelines. RevMan v5.4 was used for meta-analyses, with both Haenszel-Mantel and generic inverse methodology deployed. Overall survival (OS) and disease-free survival (DFS) represented the primary outcome measures. Results Overall, 8 studies were included. At meta-analysis, a non-significant difference was observed for OS (hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.79-1.34, p=0.81) and DFS (HR: 1.13, 95% CI: 0.51 – 2.54, p=0.76) respectively. Moreover, no significant difference was observed in 3-year OS (odds ratio (OR): 0.91, 95% CI:P 0.73-1.12, p=0.35), with a significant improvement in 5-year OS observed in favour of surgery only cohort (OR: 1.35, 95% CI 1.01-1.80, p=0.04). Conclusion This meta-analysis adds to the discussion on the curative management of c T2N0 disease with substantive evidence challenging the perception that NAT confers improved survival outcomes caveated by nuances of ongoing challenges in accurately staging the disease. The first generation of prospective, randomized clinical trials may confirm or refute these findings.
Reference Key
openalex_W7203996973 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors E Gannon, Matt Davey, Jessie Elliott, John Reynolds, Dr Noel Donlon, Carmen Mueller, Dr Lorenzo Ferri
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.341
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.341/70761282/doag077.341.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.